NCT04256707
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04256707
Title Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)
Acronym SPRINT
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Karyopharm Therapeutics Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries ISR

Facility Status City State Zip Country Details
Hadassah Ein Karem University Hospital Jerusalem Jerusalem 91120 Israel Details
University Hospital Assuta Ashdod Ashdod 7747629 Israel Details
Soroka University Medical Center Beersheba 84101 Israel Details
Oncology Department Hillel Yaffe Medical Center Hadera 38100 Israel Details
Rambam Health Care Campus Haifa 3109601 Israel Details
Shaarei Zedek Medical Center Jerusalem 9103102 Israel Details
Meir Medical Center Kfar Saba 4428164 Israel Details
Galilee Medical Center Nahariya 22100 Israel Details
Rabin Medical Center Petah Tikva 49100 Israel Details
Tel-Aviv Sourasky Medical Center Tel Aviv 64239 Israel Details
Sheba Medical Center Tel Litwinsky 5265601 Israel Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field